The scientific background of Modiblast therapy has been described in numerous peer-reviewed publications. Over the years, our Helga Schmetzer has authored a total of more than 200 papers, posters, congress contributions and review articles, of which more than 30 focus on the immunobiology of leukemia. A selection of her papers is listed below.

Most relevant publications for the Modiblast Technology

  1. M. Schmetzer et al., Leukemia 21(6): 1338-1341 (2007). Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell.
  2. Kremser et al., J. Immunother. 33(2): 185-199 (2010). Dendritic cells can be success­fully generated from leukemic blasts in individual patients with AML or MDS.
  3. Reuther et al., Clin. Exp. Med. 13(1): 29-48 (2013). In vitro-induced response patterns of anti-leukemic T cells: characterization by spectratyping and immunophenotyping.
  4. Schick et al., J. Immunother. 36(4): 223-237 (2013). Anti-leukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations.
  5. Vogt et al., J. Immunother. 37(6): 331-347 (2014). Profiles of activation, differentiation-markers, or b-integrins on T cells contribute to predict T cells’ anti-leukemic responses after stimulation with leukemia-derived dendritic cells.
  6. H.-J. Kolb et al., Leukemia Suppl. 3(1): S16-S17 (2014). Mechanisms of graft-versus-leukemia effects after allogeneic stem cell transplantation: effects on the leukemia stem cell?
  7. L. Boeck et al., J. Immunother. 40(6): 224-248 (2017). Significance of Frequencies, Compositions, and/or Anti-leukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
  8. Hirn-Lopez et al., J. Immunother. 42(5): 143-161 (2019). Role of Interferon (IFN)α in “Cocktails” for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Anti-Leukemic Reactions.
  9. C. Amberger et al., Int. J. Mol. Sci. 20(18): 4590 (2019). PGE1-Containing Protocols Generate Mature (Leukemia-Derived) Dendritic Cells Directly from Leukemic Whole Blood.
  10. Ansprenger et al., Clin. Immunology 217: 108467 (2020). Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) – With a focus on Dendritic cells of leukemic origin (DCleu).
  11. Eiz-Vesper and H. M. Schmetzer, Transfus. Med. Hemother. 47(6): 429-431 (2020). Antigen-Presenting Cells: Potential of Proven und New Players in Immune Therapies.
  12. C. Amberger and H. M. Schmetzer, Transfus. Med. Hemother. 47(6): 432-443 (2020). Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.
  13. K. Klauer et al., Transfus. Med. Hemother. 49(1): 44-61 (2022). Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro.
  14. Freudenreich et al., Transfus. Med. Hemother. 45(2): 104-118 (2020). In Vitro Generated Dendritic Cells of Leukemic Origin Predict Response to Allogeneic Stem Cell Transplantation in Patients With AML and MDS.